Skip to main content

CemiplimAb Survivorship Epidemiology

Completed · NCT03836105

Conditions: Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma

At a glance

Research payments reported, 2025
$204,258
U.S. investigators named
33
Sites paid
32
Planned or actual enrollment
287

About the trial

Sponsor
Regeneron Pharmaceuticals
Tested
cemiplimab (drug)
Dates
Started 2019-06-27; completion 2025-09-29
Results posted
Not yet

The objectives of the study are: * To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) cutaneous squamous cell carcinoma (CSCC) and patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) basal cell carcinoma (BCC) in real-world clinical settings * To evaluate the safety of cemiplimab based on incidence of treatment related immune-related adverse events (irAEs), infusion related reactions (IRRs), and treatment related serious adverse reactions (TSARs) in patients with advanced CSCC and patients with advanced BCC receiving …

From ClinicalTrials.gov, last updated 2025-10-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $204,258 in research payments for this study in 2025 (81 payments).

Products named: Libtayo

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.